Current recommendations restrict the use of LAM to ambulatory patients with signs and symptoms of TB and CD4 ≤ 100 cells/μl and are based on studies that have found a lower sensitivity of LAM in patients with CD4 > 100 cells/μl [8,21–24]. This evidence concerns the gene CD4 and tuberculosis.